Clinical Trial Update: Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the CFAR regimen (cyclophosphamide, fludarabine, alemtuzumab, rituximab) in relapsed or refractory chronic lymphocytic leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Cytoxan (cyclophosphamide)
• Fludara (fludarabine)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2011-10-21